Who is sponsoring NCT07002931?

NCT07002931 is sponsored by Basma Alsheikh.

What drugs are being tested in NCT07002931?

Interventions in NCT07002931: Prebent titanium mesh augmentation, Customized PEEK mesh augmentation.

What condition does NCT07002931 study?

NCT07002931 studies Alveolar Bone Atrophy.

Is NCT07002931 still recruiting?

NCT07002931 is currently completed. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT07002931

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Titanium Mesh vs Customized PEEK Mesh for Horizontal Maxillary Ridge Augmentation: A Randomized Clinical Trial

Completed NA Last updated 8 April 2026

What this trial tests

NA trial testing Prebent titanium mesh augmentation in Alveolar Bone Atrophy in 14 participants. Completed in 1 February 2026.

Timeline

1 July 2025

Primary endpoint
1 January 2026

1 February 2026

Quick facts

Lead sponsor	Basma Alsheikh
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	14
Start date	1 July 2025
Primary completion	1 January 2026
Estimated completion	1 February 2026
Sites	1 location across Egypt

Drugs / interventions tested

Prebent titanium mesh augmentation
Customized PEEK mesh augmentation

Conditions studied

Alveolar Bone Atrophy — all drugs for Alveolar Bone Atrophy →

Sponsor

Basma Alsheikh

Who can join

Adults 18 to 70, any sex, with Alveolar Bone Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Reconstruction of the deficient maxillary ridge in three dimensions is crucial for the successful placement of implants. Prebent titanium meshes are an established modality for GBR, while patient-specific PEEK meshes have recently emerged with some possible advantages over the former. This study compared the effectiveness of these two modalities for bone augmentation. Materials and Methods: 14 patients with 28 augmented sites in the maxillary ridges of primarily horizontal bone deficiencies, often associated with minor vertical components, were randomly assigned to two groups. The control group (n=7) was augmented with a prebent titanium mesh, while the study group (n=7) was augmented with a customized milled PEEK mesh. Both were grafted with a mixture of autogenous bone and xenograft. The primary outcome was horizontal bone gain. Secondary outcomes included vertical bone gain, gained bone volume, and graft resorption. These parameters were assessed by CBCT preoperatively, immediately postoperatively, and at 6 months before implant placement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alveolar Bone Atrophy

Currently open trials in the same condition.

NCT07162389 — Comparative (Short vs. Standard) Length Implants in Early Stability Patterns. · NA · active not recruiting
NCT07526337 — Digital Planning and Clinical Assessment of the Treated Atrophic Posterior Maxilla With a Sinus Lift Procedure: a Cross- · recruiting
NCT07526129 — Impact of Alveolar Ridge Preservation on the Potential Need for Sinus Floor Elevation: A 10-year Retrospective Radiograp · recruiting
NCT07424742 — Graftless TSFE Via Self-tapping Implants · NA · recruiting

Other Basma Alsheikh trials

Trials by the same sponsor.

NCT07040124 — Assessment of Efficacy of Prebent Titanium Mesh Versus Customized Poly-ether Ether Ketone Mesh for Three Dimensional Aug · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07002931 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Basma Alsheikh
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07002931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing